March 13th 2025
Steqeyma is one of seven Stelara biosimilars that have been approved by the FDA.
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Lung Cancer Tumor Board: Enhancing Precision Medicine in NSCLC Through Advancements in Molecular Testing and Optimal Therapy Selection
View More
Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
PBM Exclusions Increasing, Finds New Analysis
June 7th 2022Xcenda’s review of the three largest PBMs—CVS Caremark, Express Scripts, and OptumRx—finds they are excluding medicines in classes where generics are not available or for serious conditions, such as oncology and autoimmune disorders.
Read More
Aetna Adds Recently Approved Drugs to Precertification List
May 18th 2022Aetna has made available four specialty drugs that were approved early in 2022 through prior authorization. These include a biosimilar, a CAR-T immunotherapy, and therapies for macular degeneration and a rare auto-immune disease.
Read More